UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Name of each exchange on which registered FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10585 CHURCH & DWIGHT CO., INC. (Exact name of registrant as specified in its charter) Delawa ...

文章核心观点 - 公司第三季度业绩表现出色,收入和利润同比增长[1][2][3] - 业绩增长得益于公司产品组合的强劲需求、品牌韧性、新产品推出成功以及有效执行[1] - 公司预计2024年全年销售增长约3.5%,有机销售增长约4%[11][12] - 公司预计2024年全年调整后每股收益增长约8%[13] 公司业绩概况 - 第三季度调整后每股收益0.79美元,超出市场预期[2] - 第三季度销售收入15.11亿美元,同比增长3.8%,超出市场预期[3] - 毛利率同比提升80个基点至45.2%,主要得益于生产效率提升以及有利的销量和产品组合[4] - 营销费用同比增加1800万美元至1.858亿美元,占销售收入的12.3%[4] - 销售及一般管理费用占销售收入的15%,同比上升20个基点,主要由于国际业务、研发和信息技术投入增加[5] 业务板块表现 - 消费品国内业务销售增长3.3%,有机销售增长3.3%,主要得益于THERABREATH、HERO、ZICAM等产品的强劲表现[6] - 消费品国际业务销售增长9.5%,有机销售增长8.1%,主要得益于THERABREATH、HERO和OXICLEAN等产品[7] - 专业产品业务销售下降8%,但有机销售增长7.5%,主要由于价格和产品组合改善[8] 财务状况 - 截至第三季度末,公司现金及现金等价物为7.521亿美元,长期债务为22.082亿美元[9] - 前三季度经营活动产生的现金流为8.639亿美元,资本支出为1.252亿美元[10] - 公司预计2024年全年经营活动产生的现金流将达到约11亿美元[10]

财务数据和关键指标变化 - 第三季度报告的销售增长为3.8%，超出预期的2.5% [4] - 有机销售增长4.3%，高于预期的3% [5] - 调整后的每股收益为0.79美元，比预期的0.67美元高出0.12美元 [6][27] - 调整后的毛利率为45%，较去年增加60个基点 [28] 各条业务线数据和关键指标变化 - 美国业务有机销售增长3.3%，连续五个季度实现销量增长 [7] - 国际业务有机增长8.1%，符合预期 [22] - 专业产品有机销售增长7.5%，连续三个季度实现稳定增长 [23] - 个人护理中的维生素业务仍然拖累整体有机增长，消费下降10% [14] 各个市场数据和关键指标变化 - 在线销售占全球销售的约21% [6] - 口腔护理市场中，THERABREATH的市场份额为35%，在非酒精类漱口水中占据第一 [17] - HERO品牌在痤疮护理市场中占据22%的市场份额，继续推动该类别的增长 [19] 公司战略和发展方向和行业竞争 - 公司计划在2025年之前继续投资于创新和市场营销，以支持未来的增长 [34][56] - 在竞争激烈的市场中，公司将专注于创新和市场份额的提升，而不是通过降价来争夺市场 [92] - 公司对维生素业务的未来持谨慎态度，计划在2025年推出新的创新产品以刺激增长 [47][50] 管理层对经营环境和未来前景的评论 - 管理层对美国消费者和类别增长率持谨慎态度，预计第四季度的消费将受到影响 [25][34] - 尽管面临挑战，管理层对公司在各个业务线的表现感到乐观，认为未来将继续实现增长 [26][34] 其他重要信息 - 公司在第三季度的现金流为8.64亿美元，预计全年现金流将达到约11亿美元 [32] - 预计2024年的资本支出将达到约1.8亿美元 [33] 问答环节所有提问和回答 问题: 关于第四季度的展望 - 管理层表示，零售库存的变化对第四季度的影响不大，消费趋势可能会减缓 [38] - 管理层对未来的消费趋势持谨慎态度，认为可能会出现放缓 [40] 问题: 关于维生素业务的稳定和增长路径 - 管理层提到，维生素业务的创新将在2025年推出，预计将有助于业务的稳定 [47][50] 问题: 关于市场营销投资的增加 - 管理层确认，第四季度的市场营销支出将增加，主要用于支持新产品的推广 [52][54] 问题: 关于促销环境的变化 - 管理层表示，尽管竞争对手的促销活动增加，但公司不会追求低价竞争，而是专注于创新 [92][94] 问题: 关于国际业务的表现 - 管理层表示，国际业务在多个市场表现良好，未来将继续进行机会性投资 [129] 问题: 关于创新的贡献 - 管理层提到，创新对2024年的销售增长贡献约为2% [109]

For the quarter ended September 2024, Church & Dwight (CHD) reported revenue of $1.51 billion, up 3.8% over the same period last year. EPS came in at $0.79, compared to $0.74 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.49 billion, representing a surprise of +1.12%. The company delivered an EPS surprise of +16.18%, with the consensus EPS estimate being $0.68.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Church & Dwight (CHD) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.18%. A quarter ago, it was expected that this maker of household and personal products would post earnings of $0.84 per share when it actually produced earnings of $0.93, delivering a surprise of 10.71%.Over the ...

CHURCH & DWIGHT CO., INC. News Release Contact: Rick Dierker Chief Financial Officer 609-806-1200 CHURCH & DWIGHT REPORTS Q3 2024 RESULTS Q3 NET SALES, GROSS MARGIN, ADJUSTED EPS AND CASH FLOW EXCEED OUTLOOK AFFIRMS FULL YEAR NET SALES AND ADJUSTED EPS OUTLOOK 2024 Third Quarter Results 2024 Full Year Outlook • Net Sales +3.8%: Domestic +3.3%, Int'l +9.5%, SPD -8.0% • Net Sales +3.5%; Organic Sales +4.0%¹ • Organic Sales¹ +4.3%: Domestic +3.3%, Int'l +8.1%, SPD • Adjusted Gross Margin expansion +110 bps (pr ...

文章核心观点 - 公司预计第三季度营收将同比增长2.6%,但净利润将同比下降8.1% [1][2] - 公司的主要品牌如Arm & Hammer、OxiClean和Trojan等有望继续成为重要的收入驱动因素 [6][7] - 公司正在加强国际市场的拓展,预计国际业务收入将同比增长8.3% [8] - 但公司也面临着消费者支出放缓等挑战,如维生素软糖业务表现不佳 [9][10] - 公司营销费用和销售费用有所上升,可能会对利润率产生一定压力 [11] 根据相关目录分别进行总结 收入情况 - 公司预计第三季度营收将同比增长2.6%,达到14.94亿美元 [1] - 其中国内消费品业务收入预计增长2%,国际消费品业务收入预计增长8.3% [7][8] 利润情况 - 公司第三季度净利润预计同比下降8.1%,每股收益为0.68美元 [2] - 营销费用和销售费用上升,可能会对利润率产生一定压力 [11] 品牌表现 - 公司主要品牌如Arm & Hammer、OxiClean和Trojan等有望继续成为重要的收入驱动因素 [6][7] - 公司在高毛利和快速增长的细分品类如美容护理和水牙线等方面持续创新,有助于提升整体盈利能力 [7] 国际业务 - 公司正在加强国际市场的拓展,预计国际业务收入将同比增长8.3% [8] - 其中加拿大、墨西哥和德国市场表现尤为出色 [8]

The upcoming report from Church & Dwight (CHD) is expected to reveal quarterly earnings of $0.68 per share, indicating a decline of 8.1% compared to the year-ago period. Analysts forecast revenues of $1.49 billion, representing an increase of 2.6% year over year.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's earni ...

Church & Dwight (CHD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Novem ...

Church & Dwight Co., Inc. (CHD) appears in a troubled spot. The company is facing challenges related to volatile consumer spending in the current environment. Increasing marketing expenditure and weakness in the gummy vitamins business are also a concern for the company's overall performance. These downsides are reflected in Church & Dwight's guidance for the third quarter and 2024. Reflecting the negative sentiment, the Zacks Consensus Estimate for the current quarter and full year has seen downward revisi ...